These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9890738)

  • 21. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The basis for radioiodine therapy in differentiated thyroid cancer].
    Haldemann AR
    Ther Umsch; 1999 Jul; 56(7):403-7. PubMed ID: 10434780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of 13-cis retinoic acid for treatment of advanced differentiated thyroid cancer].
    Handkiewicz-Junak D; Roskosz J; Turska M; Wygoda Z; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():301-6. PubMed ID: 12182039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
    Mazzaferri EL; Kloos RT
    Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of external beam radiation and targeted therapy in thyroid cancer.
    Brierley J; Sherman E
    Semin Radiat Oncol; 2012 Jul; 22(3):254-62. PubMed ID: 22687950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Differentiated thyroid cancer].
    Tiedje V; Schmid KW; Weber F; Bockisch A; Führer D
    Internist (Berl); 2015 Feb; 56(2):153-66; quiz 167-8. PubMed ID: 25627410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland.
    Kim JH; Leeper RD
    Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):565-7. PubMed ID: 6406402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
    Schaap J; Eustatia-Rutten CF; Stokkel M; Links TP; Diamant M; van der Velde EA; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):117-24. PubMed ID: 12100079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma.
    Coelho SM; Corbo R; Buescu A; Carvalho DP; Vaisman M
    J Endocrinol Invest; 2004 Apr; 27(4):334-9. PubMed ID: 15233552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
    Van Tol KM; Hew JM; Jager PL; Vermey A; Dullaart RP; Links TP
    Clin Endocrinol (Oxf); 2000 May; 52(5):653-9. PubMed ID: 10792347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
    Schraube P; Kimmig B; zum Winkel K
    Nuklearmedizin; 1984 Jun; 23(3):151-4. PubMed ID: 6435095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma.
    Taylor T; Specker B; Robbins J; Sperling M; Ho M; Ain K; Bigos ST; Brierley J; Cooper D; Haugen B; Hay I; Hertzberg V; Klein I; Klein H; Ladenson P; Nishiyama R; Ross D; Sherman S; Maxon HR
    Ann Intern Med; 1998 Oct; 129(8):622-7. PubMed ID: 9786809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
    Putzer D; Gabriel M; Kroiss A; Madleitner R; Eisterer W; Kendler D; Uprimny C; Bale RJ; Gastl G; Virgolini IJ
    Clin Nucl Med; 2012 Jun; 37(6):539-44. PubMed ID: 22614183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer.
    Kim WG; Kim EY; Kim TY; Ryu JS; Hong SJ; Kim WB; Shong YK
    Endocr J; 2009; 56(1):105-12. PubMed ID: 18854619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
    Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
    Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.